HRH. Rudert

H. Rudert

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


H. Rudert has a total of 23 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Rhinologische Orbitachirurgie

    by H. Rudert, S. Maune

    Die Nachbarschaft der Nasennebenhöhlen zu drei der vier Orbitawände impliziert vielfältige Wechselbeziehungen zwischen Ophthalmologie und Hals-, Nasen-, Ohrenheilkunde. Die Orbitachirurgie ist allein schon deshalb ein Paradebeispiel für interdisziplinäre Chirurgie [ 1 ]. Im Jahre 1993 wurde in Kiel durch Gründung des Orbitazentrums der Grundstein für eine enge interdisziplinäre Zusammenarbeit der so genannten Kopffächer (Hals-, Nasen-, Ohrenheilkunde, Kopf- und Halschirurgie, Neurochirurgie, Mund-, Kiefer-, Gesichtschirurgie, Ophthalmochirurgie) gelegt. Die unkomplizierte Zusammenarbeit der Kopf-, Halschirurgie und der Ophthalmochirurgie ergibt sich auch aus dem günstigen Umstand, dass beide Fachgebiete etwa zur gleichen Zeit die Mikrochirurgie entwickelt haben, so dass bei gemeinsamen Eingriffen das gleiche optische Instrumentarium benutzt werden kann. Der Großteil der interdisziplinär operativ versorgten Orbitaprozesse wurde durch die beiden letztgenannten Fachgebiete behandelt. Voraussetzung für jeden orbitachirurgischen Eingriff ist die Kenntnis der klassischen extranasalen und der endonasalen operativen Zugänge, der gezielte Zugang durch zumeist normale extraorbitale Strukturen sowie die adäquate chirurgische Darstellung des Befundes und dessen mikrochirurgische Entfernung ohne weitere Alteration anderer orbitaler Gewebe. Die klassische topographische Einteilung der Orbita in Etagen, Hälften und Drittel ist für die Entscheidungsfindung des optimalen operativen Zugangsweges weiterhin nützlich. Für die rhinochirurgischen Zugänge ist vor allem die Einteilung der Orbita in der Frontalebene in das vordere, mittlere und hintere Drittel wichtig. Orbitaprozesse des vorderen Drittels können vorwiegend durch den Orbitachirurgen ohne Hilfe anderer Fachdisziplinen operiert werden, während Prozesse des mittleren und hinteren Drittels interdisziplinär versorgt werden müssen.

    • 23 August 2000
      • Vol. 20  (4) , 2613-6

    p53 analysis of laryngeal cancer in exon 4 to 9.

    by S Gottschlich, S Maune, J Preugschat, M Hoffmann, J A Werner, J D Maass, T Görögh, K Heidorn, H Rudert

    P53 gene mutations are a common genetic alteration in human cancer and codon 72/exon 4 polymorphism of the p53 gene has been implicated in cancer risk. Therefore in this study the p53 gene status of 32 shock-frozen tumor specimens from larynx carcinomas was analyzed by PCR and sequencing of exon 4 through 9. Four mutations (12.5%) in exon 5, 7, 8 and 9 were detected in the carcinoma specimen. Analysis of codon 72 revealed in eight cases a homozygosity for proline (CCC) and in 24 cases heterozygosity or homozygosity for arginine (CGC). The group with the proline/proline genotype had a median age 10.3 years lower than the remaining patients and included the only two non-smokers. Firstly, these results confirm the p53 mutational status of laryngeal cancer without any clinical correlation and secondly may suggest an oncogenic potential for the proline/proline genotype of codon 72 for laryngeal cancer as has already been assumed for lung cancer.


    • 6 August 2000
      • Vol. 20, 2241-3

    Cyfra 21-1: a serological help for detection of distant metastases in head and neck cancer.

    by J D Maass, A Hoffmann-Fazel, T Goeroegh, M Hoffmann, J E Meyer, S Gottschlich, H Rudert, S Maune

    Local and neck recurrences of squamous cell carcinoma of the head and neck (SCCHN) can mostly be detected early when the patient has regular follow-ups. Distant metastases though usually remain undiscovered until they produce clinical symptoms. Since Cyfra 21-1 correlates with the tumor size and stage in SCCHN, we looked for possible connections between Cyfra 21-1 increases and the development of distant metastases. The sera of 830 patients with SCCHN were tested for Cyfra 21-1. The levels were compared with the clinical run of the patients. When Cyfra 21-1 levels rose above the threshold of 3.3 ng/ml (71 out of 830) staging procedures were performed. Tumor growth was found in 50 out of 71 patients with elevated Cyfra levels (70.4%). Cyfra serum levels in those cases either represented development of distant metastases (27 out of 71), or local and neck recurrences. The results of this study show that Cyfra 21-1 is a suitable and helpful serological parameter for the follow-up of patients with SCCHN. In the event of an elevation of Cyfra 21-1 above the threshold during follow-up, we would recommend the performance of a thoracal CT-scan and abdominal omi ultrasound as staging procedures.


    • 1 December 1997
      • Vol. 35  (4) , 161-5

    Alpha 1-receptors at pre-capillary resistance vessels of the human nasal mucosa.

    by V Johannssen, S Maune, J A Werner, H Rudert, A Ziegler

    The aim of the present study was to further characterise the alpha-adrenoceptors in pre-capillary arteries of the human nasal mucosa. Mucosa was obtained from patients undergoing endonasal surgery. From the isolated conchae small arteries (diameter: 90-220 microns) were dissected, avoiding any direct traumatisation. The arteries were mounted to a Mulvany-Halpern wire myograph allowing isometric registration of the vessel constriction. Receptor subtypes were characterised using the agonists noradrenaline, phenylephrine and oxymetazoline, and the antagonists prazosine and yohimbine. The EC50 values of the three agonists were in the micromolar range, whereas the Emax values differed. When maximal responses to the agonists were expressed as a percentage of a potassium-induced constriction, values for noradrenaline, phenylephrine and oxymetazoline amounted to 110%, 78% and 21%, respectively. The agonist effects were almost completely blocked by the alpha 1-receptor antagonist prazosine, whereas yohimbine, the alpha 2-receptor antagonist, did not affect the agonist responses. From these results it is concluded that the adrenoceptors in pre-capillary arteries of the mucosa in human central concha are of the alpha-type. Since the decongestive effect of alpha 2-receptor agonists is beyond any doubt, this subtype of the adrenoceptor must be present on the venous capacitance vessels.


    • 1 March 1997
      • Vol. 35  (1) , 2-5

    Indication, incidence and management of blood transfusion during sinus surgery: a review over 12 years.

    by S Maune, W Jeckström, H Thomsen, H Rudert

    The number of reports about blood transfusion-related HIV and hepatitis virus infections is increasing, presently. Thus, it should seriously be considered to inform the patient of any anticipated blood loss necessitating a transfusion of blood products. This is especially necessary for surgical procedures with only a low risk for high blood loss, such as endonasal surgery as a common otorhinolaryngological procedure. However, reports about the incidence of blood transfusion during this kind of surgery are very rare. The medical histories of 6,296 patients who underwent sinus surgery between 1982-1993 in the Department of Otorhinolaryngology at the University of Kiel were analyzed. Twenty-nine of these patients received a transfusion. Risk factors for required blood, the necessity of pre-operative information and the recommendation policy for pre-operative donation of autologous blood are discussed. The intra-operative blood losses of 120 patients who did not require a transfusion and who underwent sinus surgery in 1986 and 1989, were analyzed. The transfusion rate was 0.46% on average during the 12-year period. The incidence of blood transfusion and the amount of intra-operative blood loss decreased after combination of endonasal surgery with controlled intra-operative hypotension (0.07%; p < 0.01). Risk factors for the necessity of a transfusion in these cases were extensive polyposis and purulent exacerbation of the disease. There are risks for a blood transfusion in endonasal surgery. Every transfusion carries a certain risk for the infection with HIV or hepatitis, therefore every patient should be informed about the possibility of a blood transfusion prior to the operation. Endonasal microscopic sinus surgery performed by well-trained surgeons, combined with controlled intra-operative hypotension lowered the risk for a transfusion significantly (p < 0.01).


  • Untersuchungen zum löslichen Interleukin-2 Rezeptor im Serum von Patienten mit Plattenepithelkarzinomen der oberen Luft- und Speisewege1,2

    by S. Gottschlich, J. A. Werner, B. M. Lippert, T. Görögh, S. Maune, H. Rudert

    Several investigations showed increased levels of the soluble interleukin-2 receptor (sIL-2 R) in chronic and malignant diseases. A correlation between elevated sIL-2 R levels and disease activity or tumor size was observed in some patients. At present, there are no studies of sIL-2 R serum levels in patients with squamous cell carcinomas of the upper aerodigestive tract. SIL-2 R levels were measured in sera of 86 patients with squamous cell carcinoma of the head and neck and of 25 healthy controls with a sandwich ELISA. Significantly elevated serum levels of sIL-2 R were detected in 49 out of 86 patients (56.9%) with squamous cell carcinoma of the head and neck. The mean serum level in the healthy controls was 437 U/ml compared to 895 U/ml in carcinoma patients. A correlation was found between tumor size, number of metastases and the sIL-2 R level. There was no correlation with histological type or tumor localization. The physiological role of sIL-2 R is still unknown. Elevated levels of sIL-2 could be a sign of activation of the immune system. But they also might be involved in causing the disease. The sIL-2 R serum levels in patients with squamous cell carcinoma of the head and neck may serve as an unspecific indicator for tumor size and dissemination. Posttherapeutic titer controls could be of prognostic value. Additionally, sIL-2 R may help to select appropriate patients for an immunotherapy with recombinant IL-2.